aro-ang3
Nucleic acidexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jan 7, 2019 (NCT03747224)
Timeline
Indications
Mechanism of action
- Angiopoietin-related protein 3INHIBITOR
ANGPTL3 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314648 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07037771 | Phase 3 | Jun 17, 2025 | Arrowhead Pharmaceuticals |
| NCT05217667 | Phase 2 | Apr 22, 2022 | Arrowhead Pharmaceuticals |
| NCT04832971 | Phase 2 | Jun 28, 2021 | Arrowhead Pharmaceuticals |
| NCT03747224 | Phase 1 | Jan 7, 2019 | Arrowhead Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | For profit | 4 | 4 | 3 | 2019 |
1 organizations
Page 1 / 1